- For printing
- April 24, 2024
Eisai Co., Ltd. (Headquarters: Tokyo; Representative Executive Officer and CEO: Haruo Naito) has introduced the anti-amyloid beta protofibrillar antibody “RecembiI would like to inform you that global sales revenue for the fourth quarter of fiscal 2023 (2024/1/1/1 to 3/31) was 2.83 billion yen (figure before audit), which was approximately 2.7 times higher than the previous quarter (2023/10/1 to 12/31).
This information will be disclosed in conjunction with today's financial results announcement for the 1st quarter of fiscal year 2024 by Biogen Inc. (Headquarters: Cambridge, Massachusetts, USA). Our financial results for the fiscal year ending 2024/3, including details of sales revenue from “Rekembi,” are scheduled to be disclosed in our financial results announcement scheduled for 2024/5/15.
Regarding lecanemab, Eisai leads development and regulatory applications globally, and Eisai and Biogen will carry out joint commercialization and joint sales promotion under Eisai's final decision-making authority.
over